NDV-HXP-S
NDV-HXP-S
NDV-HXP-S (pronounced as N-D-V-H-X-P-S) is a novel vaccine candidate for the prevention of COVID-19. It is developed by the Program for Appropriate Technology in Health (PATH) and the Government Pharmaceutical Organization (GPO) of Thailand.
Etymology
The term NDV-HXP-S is an acronym derived from the components used in the vaccine's development. NDV stands for Newcastle Disease Virus, a type of virus used as a vector in the vaccine. HXP refers to the HexaPro, a version of the SARS-CoV-2 spike protein. S stands for Spike, the protein on the surface of the SARS-CoV-2 virus that the vaccine targets.
Development and Mechanism
The NDV-HXP-S vaccine uses a modified version of the Newcastle Disease Virus to carry the HexaPro version of the SARS-CoV-2 spike protein into the body. This stimulates an immune response, producing antibodies that can recognize and neutralize the SARS-CoV-2 virus if the person is exposed in the future.
Related Terms
See Also
External links
- Medical encyclopedia article on NDV-HXP-S
- Wikipedia's article - NDV-HXP-S
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski